Charts

Things could get better for the biotech, but they could also get worse.

Investors eyeing a purchase of bluebird bio Inc (BLUE) shares, but cautious about paying the going market price of $3.15/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2025 put at the $1.50 strike, which has a bid at the time of this writing of 30 cents..

U.S. stocks traded lower, with the Dow Jones falling around 200 points on Tuesday. Here are some big stocks recording gains in ...

These two biotechs have a lot in common, but one is much better capitalized.

Good medicines aren't always good business.

The big names behind biotech stocks no longer want to merely treat diseases, they want to cure them. But it's going to be costly.

These companies are innovators, something that can prove highly lucrative.

Find out why analysts have such high expectations for these stocks.

Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Upgrades According to Morgan Stanley, the prior rating for First Solar Inc (NASDAQ:FSLR) was changed from Underweight to Equal-Weight. ...

bluebird bio, Inc. (Nasdaq: BLUE) today announced that members of the management team will participate in fireside chats at the following upcoming investor conferences:

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco NASDAQ Future Gen 200 ETF (QQQS), we found that the implied analyst target price for the ETF based upon its underlying holdings is $40.78 per unit.

With multiple near-term growth catalysts in play, expectations are already high.

An upcoming regulatory decision could prove to be an inflection point in the biotech's life cycle.

Key Insights Institutions' substantial holdings in bluebird bio implies that they have significant influence over the...

Is this stock a value buy or a value trap?

InvestorPlace - Stock Market News, Stock Advice & Trading Tips The worries that have pushed the Nasdaq down sharply are overdone. Here are seven oversold Nasdaq stocks poised to rebound.  The post 7 Very Oversold Nasdaq Stocks to Buy Right Now appeared first on InvestorPlace. More From InvestorPlace ChatGPT IPO Could Shock the World, Make This Move Before the Announcement Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors

bluebird bio, Inc. (Nasdaq: BLUE) today announced that the U.S. Food and Drug Administration (FDA) has communicated that an advisory committee meeting will not be scheduled for lovotibeglogene autotemcel (lovo-cel). Lovo-cel is a potentially transformative one-time gene therapy for individuals living with sickle cell disease (SCD) with a proposed indication for patients ages 12 and older who have a history of vaso-occlusive events (VOEs). The Agency previously accepted the lovo-cel Biologics Licensing Application (BLA) for Priority Review and set a Prescription Drug User Fee Act (PDUFA) goal date of December 20, 2023.

U.S. stocks traded lower, with the Dow Jones falling around 400 points on Tuesday. Here are some big stocks recording gains in ...

Bluebird (BLUE) delivered earnings and revenue surprises of 6.94% and 25.96%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today reported financial results and business highlights for the second quarter ended June 30, 2023, including recent commercial and operational progress, and regulatory updates.

These two growth stocks could deliver stellar returns over the long term.

Are you feeling brave?

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Although you can try your hand at the lottery, your odds of success are probably far better with stocks with high returns. The post 3 Stocks to Buy for Lottery Jackpot Style Returns appeared first on InvestorPlace. More From InvestorPlace The #1 AI Name for 2023 Could Be About to Ignite This $20.6 Trillion Wealth Shift Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. The $1 Investment You MUST Take Advantage of Right Now The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors

Get ready for long-term gains – that’s the message from Bank of America. In a recent note, the bank lays out just why it believes that the S&P 500 will hit 5,000 by next year. That would represent a gain of about 9.5% from current levels. The bank’s chief equity technician, Stephen Suttmeier, sees the market in a secular bull phase – that is, a long-term upward trend lasting one or two decades. In his view, the secular trend started back in 2013 and is likely to hold until the latter years of th

bluebird bio, Inc. (Nasdaq: BLUE) today announced it will hold a conference call to discuss second quarter 2023 financial results and provide a commercial update on Tuesday, August 8 at 8:00 a.m. ET. In addition to providing an overview of the business, the conference call will highlight the Company’s ongoing commercial launches of SKYSONA® and ZYNTEGLO® and the market opportunity for lovo-cel.

These stocks come with significant risks. But they could generate huge returns over time.

Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) stock moved upwards by 36.1% to $8.86 during Friday's regular session. As of 13:30 EST, ...

Here is your Pro Recap of the biggest analyst picks you may have missed since yesterday: initiation at AMD, upgrades at Cisco, bluebird bio, and Helmerich & Payne. Late Wednesday, Wolfe Research initiated coverage on Advanced Micro Devices (NASDAQ:AMD) with an Outperform rating and a price target of $150.00 and added the stock to the Wolfe Alpha List as its top pick. First, the normalization of inventory, which is expected to support growth in H2/23 following excessive inventory levels in both client and data center segments.

Gainers Biodexa Pharmaceuticals Plc (NASDAQ: BDRX) rose 43% to $6.91. SMX (Security Matters) Public Limited Company (NASDAQ: ...

Gainers enVVeno Medical (NASDAQ:NVNO) shares moved upwards by 29.4% to $4.71 during Wednesday's regular session. Trading volume for ...

An analyst upgrade is fueling a double-digit rise in the biotech's shares today.

Upgrades According to Citigroup, the prior rating for First Solar Inc (NASDAQ:FSLR) was changed from Sell to Neutral. In the first ...

U.S. stocks traded higher, with the Dow Jones gaining over 250 points on Wednesday. Here are some big stocks recording gains in ...

Gainers 60 Degrees (NASDAQ:SXTP) stock rose 28.9% to $3.12 during Wednesday's pre-market session. The company's market cap stands at ...

Gainers 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP) shares surged 23.6% to $2.99 in pre-market trading after dipping 21% on ...

Wedbush boosted the price target for Domino's Pizza, Inc. (NYSE: DPZ) from $365 to $430. Wedbush analyst Nick Setyan maintained ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips It's time for another dive into the biggest pre-market stock movers as we check out all of the latest news for Wednesday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live Did Elon Musk Just Trigger a New Netscape Moment? The $1 Investment You MUST Take Advantage of Right Now The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors

Prominent YouTuberJack, aka known online as "Blue," has been accused of orchestrating an elaborate phishing scam worth ...

This company could soon commercialize its third gene therapy.

Reaching profitability could be harder than investors expect.

If the company can pull off a comeback, investors who get in now will see incredible returns. But how likely is a comeback?

Investors eyeing a purchase of bluebird bio Inc (BLUE) stock, but cautious about paying the going market price of $3.38/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2024 put at the $2.50 strike, which has a bid at the time of this writing of 55 cents..

bluebird bio, Inc. (Nasdaq: BLUE) today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for lovotibeglogene autotemcel (lovo-cel) for priority review. Lovo-cel is a potentially transformative one-time gene therapy for individuals living with sickle cell disease (SCD) ages 12 and older who have a history of vaso-occlusive events (VOEs). It is specifically designed to treat the underlying cause of SCD through the addition of a functional gene that enables production of anti-sickling adult hemoglobin and is the most deeply studied gene therapy in development for this disease. The agency has set a Prescription Drug User Fee Act (PDUFA) goal date of December 20, 2023.

Editas Medicine and Bluebird Bio have been favorite targets for short-sellers lately.

The FDA has accepted the application forVertex Pharmaceuticals IncorporatedandCRISPR Therapeutics AG(NASDAQ: ...

Within the last quarter, bluebird bio (NASDAQ:BLUE) has observed the following analyst ratings: Bullish Somewhat ...

Upgrades For Banco Latinoamericano de Comercio Exterior SA (NYSE:BLX), Credit Suisse upgraded the previous rating of Neutral to ...

Keybanc boosted the price target for Pure Storage, Inc. (NYSE: PSTG) from $35 to $40. Keybanc analyst Thomas Blakey maintained the ...

A clinical-stage gene therapy company is making splashes in the medical world. Genprex, Inc. (NASDAQ: GNPX) is developing potentially ...

It's facing a few issues that are practically guaranteed to affect shareholder returns.

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Russell 3000 ETF (VTHR), we found that the implied analyst target price for the ETF based upon its underlying holdings is $209.96 per unit.

Gainers GD Culture Group Limited (NASDAQ: GDC) shares climbed 121.9% to $9.63 after gaining over 8% on Monday. GD Culture ...

bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today reported financial results and business highlights for the first quarter ended March 31, 2023, including recent commercial and operational progress, and regulatory updates.

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track ...